- UCB Raises 2025 Revenue Forecast, Citing Strong BIMZELX® Performance
BRUSSELS – Global biopharmaceutical company UCB announced on Friday an upgraded financial forecast for 2025, raising its revenue expectation to exceed €7.6 billion.
The company attributed the revision to robust year-to-date performance, led by the outperformance of its key growth drivers.
The announcement was made from UCB’s headquarters in Brussels on December 5, 2025. The company stated the upgraded guidance is primarily driven by its five major growth products, with the immunology drug BIMZELX® surpassing expectations due to strong patient demand and a favorable U.S. payer mix. Continued growth from other products, including RYSTIGGO®, ZILBRYSQ®, FINTEPLA®, and EVENITY®, also contributed to the revised outlook.
Alongside the 24% year-on-year revenue growth, UCB anticipates its 2025 adjusted EBITDA margin will be higher than 31%. This figure excludes a non-recurring benefit from the sale of some established brands, part of an ongoing portfolio-simplification strategy. The company said the underlying profitability is bolstered by an improved gross margin profile and greater operating leverage.
Kroger to Pay Ocado $350M After Closing Automated Warehouses
This strong performance reinforces UCB’s confidence in its long-term growth plans, despite acknowledging the expected loss of exclusivity for its drug BRIVIACT® in 2026.
“UCB’s continued growth reflects our unwavering commitment to delivering value for patients and executing our strategic vision,” said Sandrine Dufour, CFO of UCB. The company will release its full 2025 results on February 26, 2026.
Update: U.S. Establishes Strategic Bitcoin Reserve in Landmark Executive Order